Celcuity Stock Rises on First Analyst Coverage with Bullish $150 Price Target

Apr 29, 2026

Shares of Celcuity climbed nearly 4% on Monday after an analyst began covering the stock for the first time. The coverage was initiated by Citizens analyst Silvan Turkcan, according to a report from Yahoo Finance.

Analyst Sets Bullish Price Target

Before the market opened, Turkcan assigned a market outperform rating, equivalent to a buy, and set a price target of $150 per share. That target is roughly 20% above Celcuity’s most recent closing price and ranks among the highest on Wall Street for the company.

Focus on Lead Drug Candidate

Turkcan’s analysis centers on gedatolisib, Celcuity’s experimental therapy for advanced breast cancer. The Food and Drug Administration is scheduled to complete its review of the company’s New Drug Application for gedatolisib in less than two months. The analyst noted that the drug, considered one of the more promising oncology treatments under review, could eventually be approved for indications beyond breast cancer, which would add significant value to both the drug and its developer.

Market Interest in Oncology

Celcuity has attracted attention from biotech investors due to the high potential of gedatolisib and its strong chance of FDA approval in the near term. While the stock is expensive, the drug’s potential alone could further increase the company’s value.

This report provides a comprehensive view of the medicaments containing vitamins industry in the United States, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the medicaments containing vitamins landscape in the United States.

Quick navigation

• Key findings
• Report scope
• Product coverage
• Country coverage
• Methodology
• Forecasts to 2035
• Price analysis
• Market participants
• Country profiles
• How to use this report
• FAQ

Key findings

• Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
• Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
• Supply depends on input availability and production efficiency, creating a distinct national cost curve.
• Market concentration varies by segment, creating different competitive landscapes and entry barriers.
• The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.

Report scope

The report combines market sizing with trade intelligence and price analytics for the United States. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.

• Market size and growth in value and volume terms
• Consumption structure by end-use segments
• Production capacity, output, and cost dynamics
• Trade flows, exporters, importers, and balances
• Price benchmarks, unit values, and margin signals
• Competitive context and market entry conditions

Product coverage

• Prodcom 21201360 – Medicaments containing vitamins, provitamins, derivatives and intermixtures thereof, for therapeutic or prophylactic uses, put up in measured doses or for retail sale

Country coverage

• United States

Country profile and benchmarks

This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for the United States. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

• International trade data (exports, imports, and mirror statistics)
• National production and consumption statistics
• Company-level information from financial filings and public releases
• Price series and unit value benchmarks
• Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links medicaments containing vitamins demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in the United States.

• Historical baseline: 2012-2025
• Forecast horizon: 2026-2035
• Scenario-based sensitivity to income growth, substitution, and regulation
• Capacity and investment outlook for major producing companies

Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

• Price benchmarks by country and sub-region
• Export and import unit value trends
• Seasonality and calendar effects in trade flows
• Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

• Business focus and production capabilities
• Geographic reach and distribution networks
• Cost structure and pricing strategy indicators
• Compliance, certification, and sustainability context

How to use this report

• Quantify domestic demand and identify the most attractive segments
• Evaluate export opportunities and prioritize target destinations
• Track price dynamics and protect margins
• Benchmark performance against leading competitors
• Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of medicaments containing vitamins dynamics in the United States.

FAQ

What is included in the medicaments containing vitamins market in the United States?

The market size aggregates consumption and trade data, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which benchmarks are included?

The report benchmarks market size, trade balance, prices, and per-capita indicators for the United States.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

Loading News content from Store report…

Pfizer Inc.

Major producer of supplements & vitamins

Johnson & Johnson

Brands like Zarbee’s Naturals

Bayer AG (US Consumer Health)

One A Day, Flintstones brands

Procter & Gamble

Vicks, Metamucil with vitamins

AbbVie Inc.

Includes Allergan aesthetics supplements

Amway

Direct selling of vitamin brands

Church & Dwight Co., Inc.

Vitafusion, L’il Critters brands

Nestlé Health Science US

Garden of Life, Pure Encapsulations

Reckitt Benckiser Group (US)

MegaFood, Airborne brands

The Nature’s Bounty Co.

Nature’s Bounty, Sundown Naturals

NOW Health Group, Inc.

NOW Foods brand

General Mills

Via subsidiary brands

Kellogg Company

Via subsidiary brands

Herbalife Nutrition Ltd.

Direct selling model

GNC Holdings, LLC

Manufactures own brand products

The Clorox Company

Sold NeoCell brand (divested 2024)

Bristol Myers Squibb

Medical nutrition products

Perrigo Company plc

Leading store brand manufacturer

i-Health, Inc.

Culturelle, UpCal D brands

Thorne HealthTech, Inc.

Sold to L Catterton (2024)

Ritual

Direct-to-consumer brand

Life Extension

Direct brand

Jarrow Formulas, Inc.

Independent brand

Nature’s Way Brands, LLC

Nature’s Way, Alive! brands

Rainbow Light

Brand now part of Nestle

Doctor’s Best, Inc.

Independent brand

MegaFood

Part of Reckitt

Garden of Life

Part of Nestle Health Science

Pure Encapsulations

Part of Nestle Health Science

SmartyPants Vitamins

Part of Unilever

Loading Reviews content from Store report…

Loading Dashboard content from Store report…

Loading Macro Indicators content from Store report…